• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

neovasc

Shockwave Medical completes Neovasc acquisition

April 11, 2023 By Sean Whooley

Shockwave Medical (Nasdaq:SWAV) announced today that it completed its $147 million acquisition of Neovasc. In January, Shockwave announced an agreement to acquire all of the issued and outstanding common shares of Neovasc. The company paid $27.25 per share upfront by way of a statutory plan of arrangement. The deal has an enterprise value of approximately […]

Filed Under: Business/Financial News, Cardiovascular, Catheters, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: neovasc, Shockwave Medical

Shockwave Medical to acquire Neovasc for up to $147M

January 17, 2023 By Danielle Kirsh

Shockwave Medical (NSDQ:SWAV) today announced it signed an agreement to acquire all of the issued and outstanding common shares of Neovasc (NSDQ:NVCN). Neovasc enrolled its first patient in a clinical trial studying the Neovasc Reducer in January 2022. The company designed the device to reduce angina symptoms in people with refractory angina. It was also reportedly […]

Filed Under: Business/Financial News, Cardiovascular, Featured, Mergers & Acquisitions, News Well Tagged With: neovasc, Shockwave Medical

New CMS codes for angina detection, tracking benefit Neovasc

September 15, 2022 By Sean Whooley

Neovasc (Nasdaq:NVCN) announced today the Centers for Medicare and Medicaid Services (CMS) developed favorable new codes. The new codes cover the diagnosis and tracking of refractory angina. Neovasc develops the Reducer system for reducing angina symptoms in those with refractory angina. According to a news release, the codes will be utilized in the current, 10th […]

Filed Under: Business/Financial News, Cardiac Implants, Cardiovascular, Catheters, Medicare, Structural Heart Tagged With: Centers for Medicare and Medicaid Services (CMS), neovasc

Neovasc enrolls first patient in refractory angina treatment trial

January 5, 2022 By Sean Whooley

Neovasc (NSDQ:NVCN) announced today that it enrolled the first patient in the Cosira-II clinical trial for its Neovasc Reducer. Vancouver, Canada-based Neovasc’s Cosira-II (coronary sinus reducer for the treatment of refractory angina) pivotal trial will study the safety and effectiveness of the Reducer in reducing angina symptoms in those with refractory angina. According to a […]

Filed Under: Cardiac Implants, Cardiovascular, Catheters, Clinical Trials, Featured, Food & Drug Administration (FDA), Pre-Market Approval (PMA), Regulatory/Compliance, Structural Heart Tagged With: neovasc

Neovasc raises $6.1M

December 8, 2020 By Sean Whooley

Neovasc (NSDQ:NVCN) announced that it entered into agreements for the sale of its common shares worth approximately $6.1 million. Vancouver, Canada-based Neovasc sold an aggregate of more than 6.2 million common shares at a purchase price of 98¢ per share in the registered direct offering, according to a news release. Aggregate proceeds are expected to come […]

Filed Under: Business/Financial News, Cardiac Implants, Cardiovascular, Featured, Funding Roundup, Replacement Heart Valves, Structural Heart Tagged With: neovasc

FDA panel advises against assurable effectiveness of Neovasc Reducer

October 28, 2020 By Sean Whooley

Neovasc (NSDQ:NVCN) announced that an FDA advisory panel voted against reasonable assurance of effectiveness for its Reducer system. The FDA’s Circulatory System Devices Advisory Panel voted 1 to 17 “against” on the issue of “a reasonable assurance of effectiveness,” according to a news release. “We would like to thank the FDA, the panel and members of […]

Filed Under: Blood Management, Cardiac Implants, Cardiovascular, Featured, Food & Drug Administration (FDA), Pre-Market Approval (PMA), Regulatory/Compliance, Structural Heart Tagged With: FDA, FDA advisory panels, neovasc

Advisory panel to vote on FDA approval of Neovasc Reducer

September 16, 2020 By Nancy Crotti

Nine years after it won the CE Mark in Europe, the Neovasc (NSDQ:NVCN) Reducer device, designed to treat refractory angina, is close to an FDA decision on premarket approval. The agency’s Circulatory Systems Devices Panel is scheduled to discuss the Reducer at a virtual meeting set for Oct. 27, the FDA announced today. In a […]

Filed Under: Cardiac Implants, Cardiovascular, Featured, Food & Drug Administration (FDA), Implants, Pre-Market Approval (PMA), Regulatory/Compliance Tagged With: FDA, neovasc

Neovasc closes $11.5m offering

June 17, 2020 By Sean Whooley

Neovasc (NSDQ:NVCN) annunced that it closed a previously announced registered direct offering worth approximately $11.5 million. The offering includes nearly 3.9 million units, consisting of one common share of the company and three-quarters of one warrant to purchase one common share. Each warrant entitles the holder to acquire one common share of the company at $2.88 […]

Filed Under: Business/Financial News, Cardiac Implants, Cardiovascular, Funding Roundup, Replacement Heart Valves, Structural Heart, Vascular Tagged With: neovasc

Neovasc to seek CE Mark for Tiara transapical mitral valve repair device

March 4, 2020 By Sean Whooley

Neovasc (NSDQ:NVCN) announced that it plans to win CE Mark approval for its TA Tiara under the new European Medical Device Regulation (EU MDR) by 2021 or earlier. The company said it has treated 82 patients to date with the transapical (TA) Tiara mitral valve repair device. After reviewing the clinical data from its Tiara I […]

Filed Under: Cardiovascular, Featured, Regulatory/Compliance, Replacement Heart Valves, Vascular Tagged With: CE Mark, neovasc

Neovasc Reducer gains FDA PMA review

January 15, 2020 By Danielle Kirsh

Neovasc said it received FDA administrative acceptance review notification for its Reducer device. Reducer is designed to treat refractory angina, which occurs when the coronary arteries deliver an inadequate supply of blood to the heart. “I would like to reiterate my thanks to the entire Neovasc team for their tireless efforts to complete the submission […]

Filed Under: Cardiovascular, Pre-Market Approval (PMA) Tagged With: neovasc

Neovasc closes $10m direct offering

January 7, 2020 By Sean Whooley

Neovasc (NSDQ:NVCN) announced that has it closed its previously announced registered direct offering for aggregate gross proceeds reaching approximately $10 million. The Vancouver, Canada-based company sold nearly 1.2 million Series A units at $4.1351 per unit and more than 1.2 million Series B units at $4.135 per unit. Each Series A unit includes one common share […]

Filed Under: Business/Financial News, Cardiovascular, Funding Roundup, Replacement Heart Valves, Structural Heart Tagged With: neovasc

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 8
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy